Celltrion Opens Up Canadian Market For Remsima SC
Launches Subcutaneous Version Of Biosimilar Infliximab Rival To Remicade
Executive Summary
Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.
You may also be interested in...
Celltrion Eyes Remsima SC Launches In Canada And Australia
While Celltrion has delivered an unimpressive first quarter of 2021, the company has pointed to plans to launch high-margin products in new markets. The Korean firm said that it was looking to launch its subcutaneous Remsima SC infliximab formulation in Canada and Australia in 2021, while it is also aiming to launch its Yuflyma (adalimumab) in more than 70% of the EU adalimumab market.
Celltrion’s Remsima SC Will No Longer Need IV Loading
Celltrion has received an endorsement from the European Medicines Agency that means that its Remsima SC subcutaneous formulation of infliximab can be used directly in rheumatoid arthritis patients, without the need for intravenous loading first.
Canada Approves Celltrion’s Remsima SC Biosimilar
Health Canada has approved Celltrion’s subcutaneous version of Remsima for rheumatoid arthritis, as Celltrion plans to expand indications for the infliximab biosimilar to allow it to also treat inflammatory bowel disease. The company has also established an offshoot in Canada that will allow it to sell Remsima SC directly.